Sip Less. Weigh Less. Live Better. 🍷⬇️⚖️✨

About this episode

The episode discusses a clinical trial showing the efficacy of semaglutide in treating alcohol use disorder and its implications for addiction medicine.

A fascinating Lancet RCT shows once-weekly semaglutide may redefine alcohol use disorder treatment. 🎯 In 108 adults with AUD and obesity, semaglutide reduced heavy drinking days by –13.7 percentage points vs placebo (p=0.0015) and improved craving, consumption, and biomarkers. 📉 With an NNT of ~4.3 and a manageable safety profile, GLP-1 therapy signals a shift from abstinence to precision harm reduction . 💡 Efficacy. Safety. Meaningful impact. Is this the beginning of a new era in addiction medicine? 🧠💉

People in this episode

Host: Dr RR Baliga

Topics covered

• alcohol use disorder
• semaglutide
• addiction medicine
• harm reduction
• clinical trial
• obesity treatment

Keywords

• semaglutide
• alcohol use disorder
• RCT
• harm reduction
• addiction medicine
• clinical trial
• obesity
• craving
• biomarkers

Mentioned in this episode

Organizations: Lancet, GLP-1

Products: semaglutide

Places: AUD

More episodes of Dr RR Baliga's "Got Knowledge Doc" Podkast

• 🎯 Septic Shock, Hemodynamic Support, A Neutral Trial with Important Lessons · June 12, 2026 · 4 min
• One Syndrome, Three Systems, Infinite Consequences: The 2026 CKM Guideline for Integrated Cardiovascular–Kidney–Metabolic Care · June 11, 2026 · 8 min
• Earlier. Smarter. Stronger ⚡ — 🫀 — The 2026 ACC/AHA Dyslipidemia Playbook · June 10, 2026 · 10 min
• Great Doctors Series: Herophilus and the Birth of Scientific Anatomy ⚕️🌍 · June 9, 2026 · 3 min
• 🫀 The Heart on Fire: New Frontiers in Cardiovascular Inflammation · June 8, 2026 · 3 min
• 🫁 Predict, Prevent, Protect: Plasma Signals That Foretell Lung Cancer Years Ahead · June 7, 2026 · 4 min